Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_2
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Not yet recruiting2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 32 (50.0%)

Trials by Status

active_not_recruiting125%
not_yet_recruiting250%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
not_yet_recruitingphase_3

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

NCT07544654
not_yet_recruitingphase_2

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

NCT07561645
recruitingphase_3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

NCT07472517
active_not_recruitingphase_1

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

NCT05879978

Clinical Trials (4)

Showing 4 of 4 trials
NCT07544654Phase 3

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Not Yet Recruiting
NCT07561645Phase 2

A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung

Not Yet Recruiting
NCT07472517Phase 3

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Recruiting
NCT05879978Phase 1

A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Active Not Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4